A2m has been struggling to supply to meet demand. But they still...

A2m has been struggling to supply to meet demand. But they still managed to increase revenue about 10%. Bal has increased a lot, from the pharmacy channel at least 20%. You would have seen this at the super market too.
I think bal at 260mil is conservative. Could be 280-300mil for fy16. Also I don't believe their ebit is similar as 1h16. Bal step 3 price increase back in November 15 by 30%. Their NPAT could be around 42-45mil.

I also think bkl is a good buy at 130 or low 130. Despite not doing so well with their infant formula, their NPAT will be 100mil fy16. This is already disregard infant formula. Bkl should be trading at 30 not 22 at $130 per share. At Pe 30 bkl worth 175.